Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for Reproxalap

Aldeyra Therapeutics (ALDX) has provided an update.

Aldeyra Therapeutics, Inc. has successfully completed the enrollment for its Phase 3 clinical trial, which is investigating the efficacy of reproxalap, a potential new treatment for dry eye disease. This significant milestone in the drug’s development was announced through a press release and marks a crucial step forward in the company’s efforts to bring reproxalap to market for patients in need.

See more insights into ALDX stock on TipRanks’ Stock Analysis page.